A5011261788- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Multiple Myeloma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Pharmaceutical Economics and Policy
- Economic and Financial Impacts of Cancer
- AI in cancer detection
- Glioma Diagnosis and Treatment
- Fungal Plant Pathogen Control
- Protein Degradation and Inhibitors
- Health Systems, Economic Evaluations, Quality of Life
- Gestational Trophoblastic Disease Studies
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Pharmacological Effects and Toxicity Studies
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- Infrared Thermography in Medicine
- Drug Transport and Resistance Mechanisms
- Biosimilars and Bioanalytical Methods
- Hematological disorders and diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Mechanisms and Therapy
Karyopharm Therapeutics (United States)
2024-2025
Global University
2024
Ipsen (United States)
2018-2021
Hackensack University Medical Center
2016
Rutgers, The State University of New Jersey
2015-2016
Oregon Health & Science University
2009
Background/Objectives: Chimeric antigen receptor T-cell therapy (CAR-T) has become a key treatment option for relapsed/refractory multiple myeloma (RRMM), but factors impairing fitness may diminish efficacy. Our exploratory analysis aimed to evaluate the impact of prior with selinexor-containing regimen on CAR-T outcomes RRMM patients. Methods: Data this retrospective cohort study were sourced from electronic medical records at two US academic centers. Kaplan-Meier estimates assessed...
Treatment for relapsed/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens. Real-world studies help to determine the optimal treatment sequences and dosing through observed usage outside clinical trials. Previous trials have demonstrated high rates durable responses in patients triple-class-exposed RRMM regimens containing selinexor, a first-in-class, orally available selective exportin 1 inhibitor....
Identification of alterations in ALK gene and development ALK-directed therapies have increased the need for accurate efficient detection methodologies. To date, research has focused on concordance between two most commonly used technologies, fluorescent situ hybridization (FISH) immunohistochemistry (IHC). However, inter-test reflects only one, albeit important, aspect diagnostic process; laboratories, hospitals, payors must understand cost workflow rearrangement strategies. Through...
To understand the quality of life (QoL) for patients with neuroendocrine tumors (NETs) through comparison QoL questionnaires and symptom tracking as well journaling via Carcinoid NETs Health Storylines mobile application (app).This was a 12-week prospective, observational study US NET who were taking long-acting somatostatin analogs. National Institutes Patient-Reported Outcomes Measurement Information System (PROMIS) European Organisation Research Treatment Cancer (EORTC) administered three...
Although recent pivotal trials (PROMID, CLARINET) have established somatostatin analogs (SSAs) as first-line agents for neuroendocrine tumors (NETs), their use in clinical practice is largely unknown. We aimed to understand real-world management and treatment of gastroenteropancreatic (GEP) NETs.Patients with metastatic GEP-NETs treated SSAs, lanreotide depot or octreotide long-acting release (LAR), between January 1, 2015, December 31, were identified from a U.S. claims database...
Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. However, each agent possesses unique attributes terms of their drug-delivery characteristics. The study objective was to compare overall efficiency between lanreotide LAR tumor patients.This employed an observational time motion design among treated across five US cancer centers. Baseline patient data...
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can result in symptoms such as diarrhea, flushing, abdominal pain, and fatigue are often associated with a significant disease burden poor prognosis. This non-interventional, prospective, observational study evaluated the real-world safety effectiveness of lanreotide depot, somatostatin analog (SSA) used to treat GEP-NETs, community setting. In this non-interventional (NCT02730104), adult patients locally advanced (inoperable),...
Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved 2014 improve progression-free survival (PFS) unresectable, well- or moderately-differentiated, locally metastatic gastroenteropancreatic NETs. Therefore, clinicians may consider sequencing therapy from octreotide lanreotide. However, current real-world outcomes data on who have made this transition is limited.
Aim: Machine learning reveals pathways to neuroendocrine tumor (NET) diagnosis. Patients & methods: with NET and age-/gender-matched non-NET controls were retrospectively selected from MarketScan claims. Predictors (e.g., procedures, symptoms, conditions for which is misdiagnosed) examined during a 5-year pre-period understand presence of time diagnosis using conditional inference trees. Results: Among 3460 patients NET, 70% had prior misdiagnosis. 10,370 included. Decision trees revealed...
Purpose: The purpose of this analysis patient-reported outcomes from the ELECT (Evaluation Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment) trial (NCT00774930) was to explore effect lanreotide on symptoms carcinoid syndrome. Specifically, post hoc designed identify most important for patients in ELECT. Methods: ELECT, placebo-controlled study with neuroendocrine tumors, evaluated during double-blind phase trial, specifically daily diarrhea flushing symptoms,...
Neuroendocrine tumors (NETs) negatively impact patients' quality of life. Octreotide long-acting release (LAR) and lanreotide depot are somatostatin analogs (SSAs) approved to treat NETs. The study objective was explore SSA treatment experiences preferences patients with NETs.Qualitative interviews were conducted in US adults (≥ 21 years) NETs who had ≥ 6 months' each transitioned from octreotide LAR within the previous year. Participants asked open-ended questions about their depot,...
Best practice (BP) in cancer care consists of a multifaceted approach comprising individualized treatment plans, evidence-based medicine, the optimal use supportive and patient education. We investigated impact BP program patients with relapsed/refractory multiple myeloma (RRMM) receiving selinexor. Features that were specific to selinexor initiating at doses ≤80 mg once weekly upfront standardized antiemetics. Study endpoints included time failure (TTF), duration therapy, dose limiting...
359 Background: The study aim was to understand neuroendocrine tumor (NET) patients’ (pts) QoL through PROMIS-29, symptom tracking and patient journaling via the Carcinoid Health Storylines mobile application (app). Methods: This 12-week prospective, observational conducted among US NET pts recruited Cancer Foundation on either Lanreotide depot (L) or octreotide LAR (O) surveys at baseline, week (w) 6, w 12 with PROMIS-29 questionnaires 4 & 8. Pts were asked monitor symptoms, mood, bowel...
aBC leads to significant direct and indirect costs. We performed a structured literature review determine how various treatments affected economic burden in aBC. searched publications indexed from January 1, 2013 September 2, 2015 (PubMed, Embase, Cochrane Library) meeting abstracts (AACR 2014-2015, ASCO Breast Cancer Symposium SABCS 2014). Eligible studies included women with hormone receptor–positive human epidermal growth factor receptor 2–negative BC treated chemotherapies and/or...